Drug · DIN 02523957
SIMLANDI
AUTO-INJECTOR
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 13, 2022; first marketed April 13, 2022.
- Drug Identification Number (DIN)
- 02523957
- Company (DIN owner)
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 6, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 40 MG | 0.4 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 5, 2022: NOC 27339New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “simlandi”. A notice may cover another product or only some lots: read it to see what it covers.
- SIMLANDI: Product QualityApril 17, 2023 · Drugs · Product quality · Type II
Other DINs named SIMLANDI
- DIN 02523949 · Marketed
- DIN 02523965 · Marketed